Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase

Journal of Gene Medicine

Volumn 9, Issue 12, 2007, Pages 1087-1094

  Nakagawa, Aya ^a,b   Makino, Hirofumi ^a   Aoki, Motokuni ^a   Miyake, Takashi ^a   Shiraya, Suguru ^a   Nakamura, Toshikazu ^a   Ogihara, Toshio ^a   Kimata, Yoshihiro ^b   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Gene therapy; Hepatocyte growth factor (HGF); Prostacyclin; Skin flap

Indexed keywords

PLASMID DNA; PROSTACYCLIN SYNTHASE; SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GENETIC TRANSFECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IN VIVO GENE TRANSFER; MALE; MICROVASCULATURE; NONHUMAN; PEDICLED SKIN FLAP; PRIORITY JOURNAL; RAT; SURVIVAL RATE; VASODILATATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTE GROWTH FACTOR; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SURGICAL FLAPS; TRANSFECTION;

RATTUS;

EID: 37349096386     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1105     Document Type: Article

References (31)

1. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973.
2. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
3. Baumgartner I, Rauh G, Pieczek A, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-884.
4. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
5. Vale PR, Losordo DW, Milliken CE, et al. Images in cardiovascular medicine: percutaneous myocardial gene transfer of phVEGF-2. Circulation 1999; 100: 2462-2463.
6. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-974.
7. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
8. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230: 466-470.
9. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as 'cytokine supplement therapy. Hypertension 1999; 33: 1379-1384.
10. Belle EV, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-390.
11. Hayashi S, Morishita. R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: down-regulation of HGF in response to hypoxia in vascular cells. Circulation 1999; 100: II301-II308.
12. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-189.
13. Aoki M, Morishita R, Taniyama Y, et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000; 7: 417-427.
14. Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-2350.
15. Morishita R, Sakaki M, Yamamoto K, et al. Impairment of collateral formation in Lp(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 2002; 105: 1491-1496.
16. Nakamura Y, Morishita R, Higaki J, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067-1072.
17. Hara S, Morishita R, Tone Y, et al. Over-expression of prostacyclin synthase inhibits growth of vascular smooth muscle cell. Biochem Biophys Res Commun 1995; 216: 862-867.
18. McFarlane RM, DeYoung G, Henry RA. The design of pedicle flap in the rat to study necrosis and its prevention. Plast Reconstr Surg 1965; 35: 177-182.
19. Kunugiza Y, Tomita N, Taniyama Y, et al. Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacyclin synthase with Shima. Jet. Gene Ther 2006; 13: 1143-1152.
20. Koike H, Morishita R, Iguchi S, et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003; 17: 779-781.
21. Hiraoka K, Koike H, Yamamoto S, et al. Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of intramuscular injection on naked plasmid DNA. Circulation 2003; 108: 2689-2696.
22. Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006; 13: 1206-1213.
23. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on up-regulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-1417.
24. Kryger Z, Zhang F, Dogan T, et al. The effects of VEGF on survival of a random flap in the rat: examination of various routes of administration. Br J Plast Surg 2000; 53: 234-239.
25. Fujihara Y, Koyama H, Nishiyama N, et al. Gene transfer of bFGF to recipient bed improves survival of ischemic skin flap. Br J Plast Surg 2005; 58: 511-517.
26. Giunta RE, Holzbach T, Taskov C, et al. AdVEGF165 gene transfer increases survival in overdimensioned skin flaps. J Gene Med 2005; 7: 297-306.
27. Huemer G, Shafighi M, Meirer R, et al. Adenovirus-mediated transforming growth factor-beta ameliorates ischemic necrosis of epigastric skin flaps in a rat model. J Surg Res 2004; 121: 101-107.
28. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203-209.
29. Makino H, Aoki M, Hashiya N, et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by upregulation of hepatocyte growth factor (HGF). Hypertens Res 2004; 27: 85-91.
30. Aoki M, Morishita R, Hayashi SI, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001; 44: 1034-1042.
31. Sawamura D, Yasukawa K, Kodama K, et al. The majority of keratinocytes incorporate intradermally injected plasmid DNA regardless of size but only a small proportion of cells can express the gene product. J Invest Dermatol 2002; 118: 967-971.